How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

32,112 results for

Hypertension Evaluation History

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Whom should you test for secondary causes of hypertension?

that all children and adolescents with a new diagnosis of hypertension undergo renal ultrasound and laboratory evaluation for renal pathology (strength of recommendation [SOR]: C, consensus-based guidelines). Specific diagnostic tests are recommended for newly diagnosed patients who have suspicious clinical findings suggestive of a secondary cause of hypertension based on the initial history (excess daytime sleepiness, palpitations, tremor, sweating); physical examination (abdominal bruit, thyromegaly (...) , malar rash); or laboratory analysis (elevated serum creatinine, low thyroid-stimulating hormone) (SOR: C, consensus-based guidelines). Patients with undifferentiated resistant hypertension should receive further directed evaluation for secondary causes (SOR: C, consensus-based guidelines). URI Citation Journal of Family Practice, 63(1) 2014: 41-42, 54. Rights OpenAccess. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. Collections hosted by hosted by

2014 Clinical Inquiries

102. Economic Evaluation of Unfractionated Heparin Versus Low-Molecular-Weight Heparin to Prevent Venous Thromboembolism in General Medical and Non Orthopedic Surgical Patients

Economic Evaluation of Unfractionated Heparin Versus Low-Molecular-Weight Heparin to Prevent Venous Thromboembolism in General Medical and Non Orthopedic Surgical Patients Economic Evaluation of Unfractionated Heparin Versus Low-Molecular-Weight Heparin to Prevent Venous Thromboembolism in General Medical and Non Orthopedic Surgical Patients | CADTH.ca CADTH Document Viewer Economic Evaluation of Unfractionated Heparin Versus Low-Molecular-Weight Heparin to Prevent Venous Thromboembolism (...) in General Medical and Non Orthopedic Surgical Patients Table of Contents Search this document Economic Evaluation of Unfractionated Heparin Versus Low-Molecular-Weight Heparin to Prevent Venous Thromboembolism in General Medical and Non Orthopedic Surgical Patients April 2017 Key Finding: Economic Evaluation The price of low-molecular-weight heparin (LMWH) has decreased since it was marketed in the mid‑1990s in Canada, while unfractionated heparin (UFH) has recently become more costly because of changes

2017 CADTH - Plasma Products

103. American Gastroenterological Association Institute Guideline on the Role of Elastography in the Evaluation of Liver Fibrosis

with compensated cirrhosis with known esophageal varices or portal hypertension, were not considered in this analysis and, therefore, endoscopic evaluation should be pursued in these patients as per standard clinical practice without consideration of a VCTE cutoff of 19.5 kPa. Guidelines of the Baveno VI Consensus Workshop further support risk stratification based on a VCTE cutoff of <20 kPa and platelet count >150,000/μL. x 19 de Franchis, R. and Baveno VI Faculty. Expanding consensus in portal hypertension (...) esophageal varices), potentially minimizing the need for routine invasive testing for portal hypertension (endoscopy, hepatic venous pressure gradient measurement)? In this context, VCTE was evaluated as an add-on triage test to better define which patients may benefit from further investigation of clinically significant portal hypertension. The diagnostic performance of a prespecified cutoff of 17.0 (±2) kPa to rule out clinically significant portal hypertension was interpreted in 3 illustrative

2017 American Gastroenterological Association Institute

104. American Gastroenterological Association Institute guideline on the role of elastography in the evaluation of liver fibrosis.

, further testing (with upper endoscopy or hepatic venous pressure gradient) to evaluate clinically significant portal hypertension may be warranted before a patient is deemed high risk for elective surgery. Total articles identified: 4577 Total studies included: 79 Weighting According to a Rating Scheme (Scheme Given) Grading of Recommendations Assessment, Development and Evaluation (GRADE) Definitions of Quality/Certainty of the Evidence High The Committee is very confident that the true effect lies (...) , prospective evaluation of the utility of VCTE as a triage test to evaluate for absence of high-risk esophageal varices (EVs) and ruling our clinically significant portal hypertension before elective surgery is warranted. Finally, although a variety of noninvasive imaging-based fibrosis assessment modalities have been developed, the committee's review focused on VCTE and magnetic resonance elastography (MRE) only; a detailed synthesis of the performance and utility of other noninvasive imaging modalities

2017 National Guideline Clearinghouse (partial archive)

105. 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society

2. General Principles e30 2.1. Definitions: Terms and Classification e30 2.2. Epidemiology and Demographics e31 2.3. Initial Evaluation of Patients with Syncope: Recommendations e31 2.3.1. History and Physical Examination: Recommendation e31 2.3.2. Electrocardiography: Recommendation e31 2.3.3. Risk Assessment: Recommendations e32 2.3.4. Disposition After Initial Evaluation: Recommendations e32 3. Additional Evaluation and Diagnosis e33 3.1. Blood Testing: Recommendations e33 3.2. Cardiovascular (...) vision” or “graying out”; and variable degrees of altered consciousness without complete loss of consciousness. Presyncope could progress to syncope, or it could abort without syncope. Unexplained syncope (syncope of undetermined etiology) Syncope for which a cause is undetermined after an initial evaluation that is deemed appropriate by the experienced healthcare provider. The initial evaluation includes but is not limited to a thorough history, physical examination, and ECG. Orthostatic intolerance

2017 American Heart Association

106. 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope

and Classification e67 2.2. Epidemiology and Demographics e67 2.3. Initial Evaluation of Patients with Syncope: Recommendations e67 2.3.1. History and Physical Examination: Recommendation e68 2.3.2. Electrocardiography: Recommendation e68 2.3.3. Risk Assessment: Recommendations e68 2.3.4. Disposition After Initial Evaluation: Recommendations e69 3. Additional Evaluation and Diagnosis e70 3.1. Blood Testing: Recommendations e70 3.2. Cardiovascular Testing: Recommendations e71 3.2.1. Cardiac Imaging (...) degrees of altered consciousness without complete loss of consciousness. Presyncope could progress to syncope, or it could abort without syncope. Unexplained syncope (syncope of undetermined etiology) Syncope for which a cause is undetermined after an initial evaluation that is deemed appropriate by the experienced healthcare provider. The initial evaluation includes but is not limited to a thorough history, physical examination, and ECG. Orthostatic intolerance A syndrome consisting

2017 American Heart Association

107. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)

this page Access provided by Volume 70, Issue 6, Pages 737–751 KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) x Tamara Isakova Affiliations Division of Nephrology and Hypertension, Department of Medicine and Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (...) KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) - American Journal of Kidney Diseases Email/Username: Password: Remember me Search Terms Search within Search Share

2017 National Kidney Foundation

108. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines | Hypertension Search Hello Guest! Login to your account Email Password (...) and Obesity e28 5.2.2. Sodium Intake e29 5.2.3. Potassium e29 5.2.4. Physical Fitness e29 5.2.5. Alcohol e29 5.3. Childhood Risk Factors and BP Tracking e31 5.4. Secondary Forms of Hypertension e32 5.4.1. Drugs and Other Substances With Potential to Impair BP Control e32 5.4.2. Primary Aldosteronism e32 5.4.3. Renal Artery Stenosis e34 5.4.4. Obstructive Sleep Apnea e34 6. Nonpharmacological Interventions e35 6.1. Strategies e35 6.2. Nonpharmacological Interventions e35 7. Patient Evaluation e38 7.1

2017 American Heart Association

109. Peer Review Practices for Evaluating Biomedical Research Grants: A Scientific Statement From the American Heart Association

their peer review practices. Recommendations for Best Practices Our review of peer review found several themes. Peer review procedures and practices have a deep history and robust procedures. A remarkable amount of thought and energy go into peer review. Robust peer review is considered the state-of-the-art standard when it comes to the evaluation of scientific proposals for funding. However, it is not a perfect process, and legitimate concerns about specific areas of peer review exist. The published (...) Peer Review Practices for Evaluating Biomedical Research Grants: A Scientific Statement From the American Heart Association Peer Review Practices for Evaluating Biomedical Research Grants: A Scientific Statement From the American Heart Association | Circulation Research Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 February 2019 February 2019 January 2019 January 2019 This site uses cookies. By continuing to browse this site you

2017 American Heart Association

110. Evaluation of Abnormal Liver Chemistries

of elevation of ALT and or AST in the clinical setting helps guide the evaluation. The evaluation of hepatocellular injury includes testing for viral hepatitis A, B, and C, assessment for nonalcoholic fatty liver disease and alcoholic liver disease, screening for hereditary hemochromatosis, autoimmune hepatitis, Wilson’s disease, and alpha-1 antitrypsin de? ciency. In addition, a history of prescribed and over-the-counter medicines should be sought. For the evaluation of an alkaline phosphatase elevation (...) the likelihood of hepatomegaly being present but in and of itself does not imply an enlarged liver is present ( 76,77 ). A fi rm Before initiation of evaluation of abnormal liver chemistries, one should repeat the lab panel and/or perform a clarifying test (e.g., GGT if serum alkaline phosphate is elevated) to confi rm that the liver chemistry is actually abnormal. Th e initial history should assess risk factors for liver diseases including viral hepatitis, meta- bolic liver disease, exposures to toxins

2017 American College of Gastroenterology

111. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines | Hypertension Search Hello Guest (...) Treatment of Hypertension 1286 8.1.3. Follow-Up After Initial BP Evaluation 1287 8.1.4. General Principles of Drug Therapy 1288 8.1.5. BP Goal for Patients With Hypertension 1290 8.1.6. Choice of Initial Medication 1290 8.2. Follow-Up of BP During Antihypertensive Drug Therapy 1290 8.2.1. Follow-Up After Initiating Antihypertensive Drug Therapy 1290 8.2.2. Monitoring Strategies to Improve Control of BP in Patients on Drug Therapy for High BP 1291 9. Hypertension in Patients With Comorbidities 1291 9.1

2017 American Heart Association

112. SPRINT: Evaluation of Intensive <120mmHg vs. Standard <140mmHg Blood Pressure Targets

SPRINT: Evaluation of Intensive <120mmHg vs. Standard <140mmHg Blood Pressure Targets RXFILES TRIAL SUMMARY SPRINT www.RxFiles.ca DEC 2015 Page 1 of 5 SPRINT 1 : Evaluation of Intensive 15% but not a high degree of comorbidity ?Those who achieve such BP control, without requiring a high number of antihypertensives and do not have difficulty tolerating adverse effects of therapy Who may not be suitable? ?Those with type-2 diabetes, history of stroke, proteinuric kidney disease or heart failure (...) SPRINT www.RxFiles.ca DEC 2015 Page 4 of 5 UNCERTAINITIES: ? To what extent are the results generalizable to patients who did not meet the inclusion/exclusion criteria? - Of US adults 13 : ?Only about 17% of hypertension patients meet the SPRINT eligibility criteria ?Only about 8% overall meet the SPRINT eligibility criteria ? Is lower better in all patients? The J-curve concept in a high CV risk population (i.e. ?BP is only bene?cial to a certain target and then becomes harmful) may be significant

2016 RxFiles

113. Patient-Level Prediction of Cardio-Cerebrovascular Events in Hypertension Using Nationwide Claims Data. (PubMed)

' medical history across all health care providers in Korea (N=51,920). To ensure the generalizability of our models, we conducted an external validation using another national sample cohort dataset, comprising one million different patients, published by the National Health Insurance Service. From each dataset, we obtained the data of 74,535 and 59,738 patients with essential hypertension and developed machine learning models for predicting cardiovascular and cerebrovascular events. Six machine (...) learning models were developed and compared for evaluating performances based on validation metrics.Machine learning algorithms enabled us to detect high-risk patients based on their medical history. The long short-term memory-based algorithm outperformed in the within test (F1-score=.772, external test F1-score=.613), and the random forest-based algorithm of risk prediction showed better performance over other machine learning algorithms concerning generalization (within test F1-score=.757, external

Full Text available with Trip Pro

2019 Journal of medical Internet research

114. Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline From the American College of Physicians and the American Academy of Family Physicians. (PubMed)

targets for the treatment of hypertension in adults aged 60 years or older.This guideline is based on a systematic review of published randomized, controlled trials for primary outcomes and observational studies for harms only (identified through EMBASE, the Cochrane Database of Systematic Reviews, MEDLINE, and ClinicalTrials.gov), from database inception through January 2015. The MEDLINE search was updated through September 2016. Evaluated outcomes included all-cause mortality, morbidity (...) Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline From the American College of Physicians and the American Academy of Family Physicians. The American College of Physicians (ACP) and the American Academy of Family Physicians (AAFP) jointly developed this guideline to present the evidence and provide clinical recommendations based on the benefits and harms of higher versus lower blood pressure

Full Text available with Trip Pro

2017 Annals of Internal Medicine

115. MKSAP: 56-year-old woman pulmonary hypertension

MKSAP: 56-year-old woman pulmonary hypertension Patent ductus arteriosus with Eisenmenger syndrome MKSAP: 56-year-old woman pulmonary hypertension | | January 19, 2019 2 Shares Test your medicine knowledge with the , in partnership with the . A 56-year-old woman is evaluated during an appointment to establish care. She has a developmental delay, and she is known to have pulmonary hypertension due to a congenital cardiac condition. There is no history of cardiac surgery. She is on low-dose (...) hands appear normal. The remainder of the physical examination is unremarkable. Which of the following is the most likely cause of this patient’s pulmonary hypertension? A. Atrial septal defect B. Patent ductus arteriosus C. Tetralogy of Fallot D. Ventricular septal defect MKSAP Answer and Critique The correct answer is B. Patent ductus arteriosus. The patient has a patent ductus arteriosus (PDA) with secondary pulmonary hypertension (Eisenmenger syndrome). Clinical features of an Eisenmenger PDA

2019 KevinMD blog

116. Interaction between low-density lipoprotein-cholesterolaemia, serum uric level and incident hypertension: data from the Brisighella Heart Study. (PubMed)

Interaction between low-density lipoprotein-cholesterolaemia, serum uric level and incident hypertension: data from the Brisighella Heart Study. Previous evidence suggest that high low-density lipoprotein cholesterol (LDL-C) and serum uric acid (SUA) levels are risk factors for endothelial dysfunction and vascular ageing. The aim of our study was to evaluate the short-term interaction between SUA, LDL-C and incident hypertension in a sample of overall healthy individuals.In January 2018, we (...) selected from the general database of the Brisighella Heart Study four groups of age and sex-matched nonhypertensive individuals with different levels of LDL-C and SUA level and examined during the 2008 population survey. Incident hypertension has been defined as the increase of SBP values over 140 mmHg and/or of DBP over 90 mmHg and or the beginning of an antihypertensive treatment.In a model adjusted for age, sex, baseline blood pressure, family history of hypertension, smoking status, BMI

2019 Journal of Hypertension

117. Prevalence of Apparent Treatment-Resistant Hypertension in the United States According to the 2017 High Blood Pressure Guideline. (PubMed)

Prevalence of Apparent Treatment-Resistant Hypertension in the United States According to the 2017 High Blood Pressure Guideline. To evaluate the prevalence of apparent treatment-resistant hypertension (aTR-hypertension) in US adults with treated hypertension by using the nationally representative National Health and Nutrition Examination Survey (NHANES).Nonpregnant US adults older than 20 years with a self-reported history of treated hypertension who had blood pressure measured in NHANES (...) cycles 2007 to 2014 were included in this study. Study participants were stratified into 4 groups according to average blood pressure and antihypertensive medication use: well-controlled hypertension, undertreated hypertension, aTR-hypertension by the 2017 guideline, and aTR-hypertension by the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) guideline. National Health and Nutrition Examination Survey sample weights were

2019 Mayo Clinic Proceedings

118. Blood pressure trajectory and category and risk of hypertensive disorders of pregnancy in nulliparous women. (PubMed)

Blood pressure trajectory and category and risk of hypertensive disorders of pregnancy in nulliparous women. Recently updated American College of Cardiology/ American Heart Association (ACC/AHA) guidelines redefine blood pressure categories as Stage 1 hypertension (systolic 130-139mmHg or diastolic 80-89mmHg), Elevated (systolic 120-129mmHg and diastolic <80mm) and Normal (<120/<80 mmHg), but their relevance to an obstetric population is uncertain.We sought to evaluate the risk of gestational (...) hypertension or preeclampsia based on early pregnancy blood pressure category and trajectory.We utilized data from the Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-Be (nuMoM2b) cohort, a prospective observational study of nulliparous women with singleton pregnancies conducted at eight clinical sites between 2010-2014. Women included in this analysis had no known history of pre-pregnancy hypertension (blood pressure ≥140/90 mmHg) or diabetes. We compared the frequency of hypertensive

2019 American Journal of Obstetrics and Gynecology

119. Natural History Study of CEP290-Related Retinal Degeneration

the natural history of CEP290-related retinal degeneration caused by a compound heterozygous or homozygous intron 26 c.2991+1655A>G mutation and to better understand the best assessments for evaluation of patients with this condition in a future interventional trial. Patients meeting the entry criteria will be enrolled in the study. Visits will occur at Screening, Baseline, and Months 3, 6, and 12, for a total duration of 1 year. Study Design Go to Layout table for study information Study Type (...) of the study (eg, uncontrolled systemic hypertension, autoimmune disease, advanced coronary artery disease, or cerebral vascular disease, other unstable or progressive cardiovascular, pulmonary, Parkinson's, liver or renal disease, cancer, or dementia). Has history or current evidence of ocular disease in either eye that, in the opinion of the Investigator, may confound assessment of this inherited retinal disease or the assessments utilized herein (eg, glaucoma, age-related macular degeneration, diabetic

2017 Clinical Trials

120. Put the Family Back in Family Health History: A Multiple-Informant Approach. (PubMed)

Put the Family Back in Family Health History: A Multiple-Informant Approach. An accurate family health history is essential for individual risk assessment. This study uses a multiple-informant approach to examine whether family members have consistent perceptions of shared familial risk for four common chronic conditions (heart disease, Type 2 diabetes, high cholesterol, and hypertension) and whether accounting for inconsistency in family health history reports leads to more accurate risk (...) assessment.In 2012-2013, individual and family health histories were collected from 127 adult informants of 45 families in the Greater Cincinnati Area. Pedigrees were linked within each family to assess inter-informant (in)consistency regarding common biological family member's health history. An adjusted risk assessment based on pooled pedigrees of multiple informants was evaluated to determine whether it could more accurately identify individuals affected by common chronic conditions, using self-reported

Full Text available with Trip Pro

2017 American journal of preventive medicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>